Alpine Global Management’s Summit Therapeutics SMMT Stock Holding History

Alpine Global Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,000	Closed	-$219K	–	232
2024 Q3	$219K	Sell	10,000 -19,149	-66%	-$268K	0.05%	130
2024 Q2	$227K	Sell	29,149 -5,851	-17%	-$31.6K	0.04%	286
2024 Q1	$145K	Buy	35,000 +5,000	+17%	+$19.9K	0.03%	174
2023 Q4	$78.3K	Hold	30,000	–	–	0.02%	169
2023 Q3	$56.1K	Hold	30,000	–	–	0.01%	143
2023 Q2	$75.3K	Sell	30,000 -115,000	-79%	-$210K	0.02%	178
2023 Q1	$254K	Sell	145,000 -57,928	-29%	-$158K	0.1%	74
2022 Q4	$862K	Buy	+202,928	New	+$369K	0.29%	37
2022 Q3	–	Sell	-300,000	Closed	-$300K	–	494
2022 Q2	$300K	Buy	+300,000	New	+$421K	0.08%	102
2022 Q1	–	Hold	0	–	–	–	118

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Alpine Global Management's SMMT Position: Q4 2024 in Review

Alpine Global Management sold out of Summit Therapeutics (SMMT) in Q4 2024, closing a stake of 10,000 shares — an estimated $219K sold.

Alpine Global Management first reported a position in SMMT in Q2 2022 and held it in 9 quarters. The position peaked at $862K in Q4 2022. 203 funds tracked by Wall St. Rank hold SMMT as of Q4 2024.

Alpine Global Management reported no remaining Summit Therapeutics position as of Q4 2024 after selling out during the quarter.
Alpine Global Management sold 10,000 Summit Therapeutics shares in Q4 2024, an estimated $219K.
Alpine Global Management first reported a position in Summit Therapeutics in Q2 2022 and held it in 9 quarters.
Alpine Global Management's Summit Therapeutics position peaked at $862K in Q4 2022.
203 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2024.

Based on Alpine Global Management's 13F filing for Q4 2024, filed 14 Feb 2025.